Literature DB >> 12856719

Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.

Andrea Manni1, Sharlene Washington, Laura Craig, Michael Cloud, James W Griffith, Michael F Verderame, Lindsay J Texter, David Mauger, Laurence M Demers, John F Harms, Danny R Welch.   

Abstract

We have recently shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. The present experiments were designed to further explore PA involvement in breast cancer metastasis, using GFP-tagged MDA-MB-435 cells that can be tracked at the single cell level. Administration of DFMO significantly reduced the number of mice with pulmonary metastasis as well as the number of metastases per mouse. Both single-cell and multicellular metastatic deposits were similarly suppressed, thus suggesting that DFMO was inhibiting lung colonization by tumor cells rather than preventing progression of single-cell deposits to overt metastasis. DFMO administration also significantly reduced local recurrences following removal of the primary tumor. Prolongation of DFMO treatment to 14 weeks did not yield a superior antimetastatic effect beyond that provided by a 10-week course of therapy. Discontinuation of DFMO, on the other hand, was associated with local regrowth of the tumors and, possibly, recurrence of pulmonary metastasis. These data provide a rationale for testing the efficacy of anti-PA treatment within the context of adjuvant therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856719     DOI: 10.1023/a:1024055522067

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  12 in total

1.  Adjuvant systemic therapy for early breast cancer: progress and controversies.

Authors:  G N Hortobagyi
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

2.  Tamoxifen: five versus ten years--is the end in sight?

Authors:  J S Abrams
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

3.  S-adenosylmethionine decarboxylase overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells.

Authors:  A Manni; S Fischer; M Franks; S Washington; R De Arment; J Griffith; L Demers; M Verderame; B Leiby; D Mauger
Journal:  Int J Oncol       Date:  2001-08       Impact factor: 5.650

4.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

5.  Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens.

Authors:  A Manni; S H Astrow; S Gammon; J Thompson; D Mauger; S Washington
Journal:  Breast Cancer Res Treat       Date:  2001-05       Impact factor: 4.872

6.  Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters.

Authors:  F Cañizares; J Salinas; M de las Heras; J Diaz; I Tovar; P Martinez; R Peñafiel
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

7.  Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells.

Authors:  Andrea Manni; Sharlene Washington; James W Griffith; Michael F Verderame; David Mauger; Laurence M Demers; Rajeev S Samant; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

8.  Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice.

Authors:  A Manni; B Badger; J Martel; L Demers
Journal:  Cancer Lett       Date:  1992-09-14       Impact factor: 8.679

9.  Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer.

Authors:  P Glikman; I Vegh; M A Pollina; A H Mosto; C M Levy
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

10.  Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer.

Authors:  A Manni; D Mauger; P Gimotty; B Badger
Journal:  Clin Cancer Res       Date:  1996-11       Impact factor: 12.531

View more
  10 in total

1.  Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells.

Authors:  Andrea Manni; Sharlene Washington; Xin Hu; James W Griffith; Richard Bruggeman; Laurence M Demers; David Mauger; Michael F Verderame
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis.

Authors:  Danny R Welch; Carlton R Cooper; Douglas R Hurst; Conor C Lynch; Michelle D Martin; Kedar S Vaidya; Michael N VanSaun; Andrea M Mastro
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells.

Authors:  Gail L Matters; Andrea Manni; Judith S Bond
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.

Authors:  Patricia S Steeg; Robin L Anderson; Menashe Bar-Eli; Ann F Chambers; Suzanne A Eccles; Kent Hunter; Kazuyuki Itoh; Yibin Kang; Lynn M Matrisian; Jonathan P Sleeman; Dan Theodorescu; Erik W Thompson; Danny R Welch
Journal:  Clin Cancer Res       Date:  2009-07-15       Impact factor: 12.531

5.  High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.

Authors:  Huaiyu Ma; Xiaoming Li; Zhijian Yang; Satoshi Okuno; Takayuki Kawaguchi; Shigeo Yagi; Michael Bouvet; Robert M Hoffman
Journal:  J Surg Res       Date:  2010-06-25       Impact factor: 2.192

6.  Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells.

Authors:  Andrea Manni; Sharlene Washington; David Mauger; Deborah A Hackett; Michael F Verderame
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment.

Authors:  Monica M Richert; Pushkar A Phadke; Gail Matters; Douglas J DiGirolamo; Sharlene Washington; Laurence M Demers; Judith S Bond; Andrea Manni; Danny R Welch
Journal:  Breast Cancer Res       Date:  2005-08-09       Impact factor: 6.466

8.  Downregulation of MTAP promotes Tumor Growth and Metastasis by regulating ODC Activity in Breast Cancer.

Authors:  Ying Zhang; Tian-Tian Zhang; Lin Gao; Ya-Nan Tan; Yu-Ting Li; Xiang-Yu Tan; Tu-Xiong Huang; Hua-Hui Li; Feng Bai; Chang Zou; Xin-Hai Pei; Bin-Bin Tan; Li Fu
Journal:  Int J Biol Sci       Date:  2022-04-24       Impact factor: 10.750

9.  DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.

Authors:  Dana-Lynn T Koomoa; Dirk Geerts; Ingo Lange; Jan Koster; Anthony E Pegg; David J Feith; André S Bachmann
Journal:  Int J Oncol       Date:  2013-02-21       Impact factor: 5.650

10.  Comparison of mouse mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound.

Authors:  Maddalena T Tilli; Angela R Parrish; Ion Cotarla; Laundette P Jones; Michael D Johnson; Priscilla A Furth
Journal:  BMC Cancer       Date:  2008-01-23       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.